Document Type : Original Article
Authors
- Mohammad Kermani-Alghoraishi, MD 1
- Hamid Sanei 2
- Kiyan Heshmat-Ghahdarijani 3
- Rahil Ghahramani 4
- Mehrdad Honarvar 5
- Masoumeh Sadeghi 4
1 Interventional Cardiology Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
2 Hypertension Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
3 Heart Failure Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
4 Cardiac Rehabilitation Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
5 Shiraz Heart and Vein Center, Shiraz, Iran
Abstract
INTRODUCTION: The generation of reactive oxygen species, which is induced by the activation of the xanthine oxidase (XO) enzymatic system, is one of the primary causes of ischemia-reperfusion injury for an ischemic heart. Allopurinol, as an XO inhibitor, plays an inhibitory role in free radical production in ST-elevation myocardial infarction (STEMI) patients. The aim of this study is to evaluate the impact of allopurinol pre-treatment on post-revascularization outcomes in patients admitted with STEMI
METHOD: Ninety patients with acute STEMI were enrolled in this randomized double-blind clinical trial and divided into two equal groups. The allopurinol group received a 600 mg allopurinol loading dose before the emergency PCI, and the control group received a placebo medication of the same shape. Thrombolysis in Myocardial Infarction (TIMI) flow, ECG changes, troponin level, and the occurrence of major cardiac events (MACE) during a 1-month follow-up were assessed.
RESULTS: In the end, 81 patients were analyzed. The mean age of the patients was 59.52(11.31) and 61.3(9.25) in the allopurinol and control groups, respectively (p = 0.49). The troponin level 48 hours after the PCI and ST-elevation regression showed no significant difference between the groups [(p = 0.25) and (p = 0.21), respectively]. TIMI flow had improved in the allopurinol group compared to the placebo (p = 0.02). The PCI success rate was 78.6% and 61.5% in the case and control groups, respectively (p = 0.09). MACE and other clinical outcomes were similar between the groups (p > 0.05).
CONCLUSION: This study revealed that allopurinol pre-treatment could improve TIMI flow in patients undergoing primary or rescue PCI in an acute STEMI setting.
Keywords
2. Nowbar AN, Gitto M, Howard JP, Francis DP, Al-Lamee R. Mortality From Ischemic Heart Disease. Circ Cardiovasc Qual Outcomes 2019; 12: e005375. https://doi.org/10.1161/CIRCOUTCOMES.118.005375
3. Vogel B, Claessen B, Arnold S, Chan D, Cohen D, Giannitsis E, et al., ST-segment elevation myocardial infarction. Nat Rev Dis Primers 2019; 5: 39. https://doi.org/10.1038/s41572-019-0090-3
4. Stebbins A, Mehta R, Armstrong P, Lee K, Hamm C, Van de Werf F, J et al., A Model for Predicting Mortality in Acute ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention. Circ Cardiovasc Interv 2010; 3: 414-422. https://doi.org/10.1161/CIRCINTERVENTIONS.109.925180
5. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med 2007; 357: 1121-1135. https://doi.org/10.1056/NEJMra071667
6. Doehner W, Landmesser U. Xanthine oxidase and uric acid in cardiovascular disease: clinical impact and therapeutic options. Semin Nephrol 2011; 31: 433-440.https://doi.org/10.1016/j.semnephrol.2011.08.007
7. Zhang J, Dierckx R, Mohee K, Clark AL, Cleland JG. Xanthine oxidase inhibition for the treatment of cardiovascular disease: an updated systematic review and meta‐analysis. ESC Heart Fail 2017; 4: 40-45.https://doi.org/10.1002/ehf2.12112
8. Rentoukas E, Tsarouhas K, Tsitsimpikou C, Lazaros G, Deftereos S, Vavetsi S. The prognostic impact of allopurinol in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. Int J Cardiol 2010; 145: 257-258. https://doi.org/10.1016/j.ijcard.2009.08.037
9. Guan W, Osanai T, Kamada T, Hanada H, Ishizaka H, Onodera H, et al., Effect of Allopurinol Pretreatment on Free Radical Generation after Primary Coronary Angioplasty for Acute Myocardial Infarction. J Cardiovasc Pharmacol 2003; 41: 699-705. https://doi.org/10.1097/00005344-200305000-00005
10. Alemzadeh-Ansari MJ, Hosseini SK, Talasaz AH, Mohammadi M, Tokaldani ML, Jalali A, Pourhosseini H. Effect of High-Dose Allopurinol Pretreatment on Cardiac Biomarkers of Patients Undergoing Elective Percutaneous Coronary Intervention: A Randomized Clinical Trial. Am J Ther 2017; 24: e723-e729. https://doi.org/10.1097/MJT.0000000000000411
11. Thygesen K, Alpert J, Jaffe A, Simoons M, Chaitman B, White H. For the Universal Definition of MI W. Third Universal Definition of Myocardial Infarction. Glob Heart 2012; 7: 275. https://doi.org/10.1016/j.gheart.2012.08.001
12. The TIMI Research Group. The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. N Engl J Med 1985; 312: 932-936. https://doi.org/10.1056/NEJM198504043121437
13. Gupta S, Gupta MM. No reflow phenomenon in percutaneous coronary interventions in ST-segment elevation myocardial infarction. Indian Heart J 2016; 68: 539-551. https://doi.org/10.1016/j.ihj.2016.04.006
14. Huang Y, Zhang C, Xu Z, Shen J, Zhang X, Du H, et al., Clinical Study on efficacy of allopurinol in patients with acute coronary syndrome and its functional mechanism. Hellenic J Cardiol 2017; 58(5): 360-365.https://doi.org/10.1016/j.hjc.2017.01.004
15. Ekeløf S, Jensen SE, Rosenberg J, Gögenur I. Reduced oxidative stress in STEMI patients treated by primary percutaneous coronary intervention and with antioxidant therapy: A systematic review. Cardiovasc Drugs Ther 2014; 28: 173-181. https://doi.org/10.1007/s10557-014-6511-3
16. Ngu JMC, Ruel M, Sun LY. Left ventricular function recovery after revascularization: comparative effects of percutaneous coronary intervention and coronary artery bypass grafting. Curr Opin Cardiol 2018; 33(6): 633-637. https://doi.org/10.1097/HCO.0000000000000566
)